115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC)
    Meeting Abstract

    Cabanillas, M. E.; Lin, J. J.; Brose, M. S.; McDermott, R. S.; Almubarak, M.; Bauman, J. R.; Casanova, M.; Kummar, S.; Lee, S. H.; Leyvraz, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC)
    Meeting Abstract

    Kang, H.; Ahn, M. J.; Keam, B.; Bowles, D. W.; Wong, D. J. L.; Ho, A. L.; Kim, S. B.; Worden, F. P.; Yun, T.; Jang, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Disparities in outcomes among hospitalized unhoused patients with cancer in the US
    Meeting Abstract

    Shah, K.; Santos, P. M. G.; Barnes, J. M.; Tao, A.; Tsai, C. J.; Chino, F.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma
    Meeting Abstract

    Mohamadpour, M.; Sherman, E. J.; Kriplani, A.; Fetten, J. V.; Dunn, L.; Michel, L. S.; Hung, K. W.; Baxi, S. S.; McDonald, E.; Conybeare, R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer
    Meeting Abstract

    Desilets, A.; Pfister, D. G.; Wong, W.; Sherman, E. J.; Fetten, J. V.; Hung, K. W.; Dunn, L.; Ho, A. L.; Michel, L. S.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
    Meeting Abstract

    Hanna, G. J.; Kaczmar, J. M.; Zandberg, D. P.; Wong, D. J. L.; Yilmaz, E.; Sherman, E. J.; Hernando-Calvo, A.; Sacco, A. G.; Chung, C. H.; Bohr, D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer
    Meeting Abstract

    Chung, C. H.; Colevas, A. D. D.; Adkins, D.; Rodriguez, C. P.; Park, J. C.; Gibson, M. K.; Burtness, B.; Johnson, F. M.; Julian, R. A.; Saba, N. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC)
    Meeting Abstract

    Wong, W.; Cracchiolo, J. R.; Riaz, N.; Ganly, I.; Sherman, E. J.; Ho, A. L.; Morris, L.; Ghossein, R. A.; Haque, S.; Hung, K. W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pathogenic germline variants in patients with endometrial cancer across diverse ancestries
    Meeting Abstract

    Liu, Y. L.; Gordhandas, S.; Arora, K.; Maio, A.; Kemel, Y.; Sheehan, M.; Salo-Mullen, E. E.; Zhou, Q.; Iasonos, A.; Selenica, P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)
    Meeting Abstract

    Banerjee, S. N.; Ring, K. L.; Van Nieuwenhuysen, E.; Fabbro, M.; Aghajanian, C.; Oaknin, A.; Colombo, N.; Santin, A.; Clamp, A. R.; Moore, K. N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save